Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:DAWN NASDAQ:IPHA NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$7.11+1.4%$5.32$2.12▼$7.55$704.72M1.771.93 million shs747,903 shsDAWNDay One Biopharmaceuticals$7.45+1.2%$7.22$5.64▼$16.76$762.80M-1.261.35 million shs191,951 shsIPHAInnate Pharma$2.20+0.6%$2.04$1.29▼$3.51$202.80M0.0484,248 shs4,891 shsTERNTerns Pharmaceuticals$7.52+0.2%$7.58$1.87▼$9.03$657.64M-0.031.18 million shs474,208 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+2.49%0.00%+34.81%+68.92%+30.54%DAWNDay One Biopharmaceuticals+1.38%-1.47%+7.60%+1.80%-48.64%IPHAInnate Pharma+4.78%+2.34%+20.66%+7.35%+13.47%TERNTerns Pharmaceuticals-7.86%-12.89%-0.13%+23.97%+7.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$7.11+1.4%$5.32$2.12▼$7.55$704.72M1.771.93 million shs747,903 shsDAWNDay One Biopharmaceuticals$7.45+1.2%$7.22$5.64▼$16.76$762.80M-1.261.35 million shs191,951 shsIPHAInnate Pharma$2.20+0.6%$2.04$1.29▼$3.51$202.80M0.0484,248 shs4,891 shsTERNTerns Pharmaceuticals$7.52+0.2%$7.58$1.87▼$9.03$657.64M-0.031.18 million shs474,208 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+2.49%0.00%+34.81%+68.92%+30.54%DAWNDay One Biopharmaceuticals+1.38%-1.47%+7.60%+1.80%-48.64%IPHAInnate Pharma+4.78%+2.34%+20.66%+7.35%+13.47%TERNTerns Pharmaceuticals-7.86%-12.89%-0.13%+23.97%+7.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$10.7150.80% UpsideDAWNDay One Biopharmaceuticals 3.00Buy$25.29239.63% UpsideIPHAInnate Pharma 2.00Hold$6.50194.92% UpsideTERNTerns Pharmaceuticals 2.56Moderate Buy$13.9285.20% UpsideCurrent Analyst Ratings BreakdownLatest IPHA, DAWN, TERN, and AQST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/23/2025TERNTerns PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/23/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$20.00 ➝ $15.0010/22/2025TERNTerns PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.0010/22/2025TERNTerns PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.0010/22/2025TERNTerns PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $14.0010/17/2025AQSTAquestive TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/14/2025TERNTerns PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.0010/13/2025DAWNDay One BiopharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/9/2025AQSTAquestive TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/9/2025AQSTAquestive TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$9.00 ➝ $12.0010/8/2025AQSTAquestive TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M12.31N/AN/A($0.66) per share-10.77DAWNDay One Biopharmaceuticals$131.16M5.81N/AN/A$4.99 per share1.49IPHAInnate Pharma$21.77M9.33N/AN/A$0.11 per share20.04TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$44.14M-$0.70N/AN/AN/A-147.38%N/A-63.87%11/3/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/AN/ATERNTerns Pharmaceuticals-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)Latest IPHA, DAWN, TERN, and AQST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025TERNTerns Pharmaceuticals-$0.32N/AN/AN/AN/AN/A11/3/2025Q3 2025AQSTAquestive Therapeutics-$0.13N/AN/AN/A$12.94 millionN/A10/29/2025Q3 2025DAWNDay One Biopharmaceuticals-$0.28N/AN/AN/A$38.20 millionN/A8/11/2025Q2 2025AQSTAquestive Therapeutics-$0.18-$0.14+$0.04-$0.14$11.32 million$10.00 million8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 million8/5/2025Q2 2025TERNTerns Pharmaceuticals-$0.28-$0.26+$0.02-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A3.533.18DAWNDay One BiopharmaceuticalsN/A9.659.53IPHAInnate Pharma3.522.21N/ATERNTerns PharmaceuticalsN/A24.7024.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%DAWNDay One Biopharmaceuticals87.95%IPHAInnate Pharma0.16%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics8.35%DAWNDay One Biopharmaceuticals6.20%IPHAInnate Pharma31.89%TERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16099.72 million91.40 millionOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableTERNTerns Pharmaceuticals4087.51 million86.20 millionNot OptionableIPHA, DAWN, TERN, and AQST HeadlinesRecent News About These CompaniesJMP Securities Maintains Terns Pharmaceuticals (TERN) Market Outperform RecommendationOctober 23 at 11:55 PM | msn.comJMP Securities Maintains Terns Pharmaceuticals (TERN) Market Outperform RecommendationOctober 23 at 11:55 PM | msn.comTerns Pharmaceuticals (NASDAQ:TERN) Price Target Lowered to $15.00 at JMP SecuritiesOctober 23 at 9:43 AM | marketbeat.comTerns Pharmaceuticals price target lowered to $15 from $20 at Citizens JMPOctober 23 at 9:04 AM | msn.comAfter a failure in red-hot GLP-1 weight-loss space, Peninsula biotech shifts focus to cancerOctober 22 at 8:34 PM | bizjournals.comTerns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' RatingOctober 22 at 4:11 PM | seekingalpha.comTerns Pharmaceuticals price target lowered to $9 from $14 at MizuhoOctober 22 at 3:34 PM | msn.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Gap Down - Time to Sell?October 22 at 12:43 PM | marketbeat.comTerns Pharmaceuticals price target lowered to $14 from $15 at BarclaysOctober 22 at 8:59 AM | msn.comTerns mothballs obesity program after phase 2 data fall shortOctober 22 at 8:59 AM | fiercebiotech.comFTerns Pharmaceuticals Posts Disappointing Data From Oral GLP-1 TrialOctober 22 at 2:14 AM | marketwatch.comTerns Pharma ends obesity drug program after mid-stage trial dataOctober 21 at 4:56 PM | reuters.comTerns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in ObesityOctober 21 at 4:05 PM | globenewswire.comTerns Pharmaceuticals (NASDAQ:TERN) Hits New 1-Year High - Time to Buy?October 17, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 17, 2025 | marketbeat.comTruist Securities Initiates Coverage of Terns Pharmaceuticals (TERN) with Buy RecommendationOctober 16, 2025 | msn.comTerns Pharmaceuticals initiated with a Buy at TruistOctober 14, 2025 | msn.comTerns Pharmaceuticals (NASDAQ:TERN) Receives Sell (D-) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Sets New 12-Month High - What's Next?October 6, 2025 | marketbeat.comMizuho Securities Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)October 5, 2025 | theglobeandmail.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)October 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025These 3 Crypto Stocks Could Get a Bump as Dollar Trust WeakensBy Nathan Reiff | September 27, 2025SharkNinja Is Flashing a Buy Signal the Market Is IgnoringBy Jeffrey Neal Johnson | October 7, 2025IPHA, DAWN, TERN, and AQST Company DescriptionsAquestive Therapeutics NASDAQ:AQST$7.10 +0.10 (+1.36%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Day One Biopharmaceuticals NASDAQ:DAWN$7.44 +0.09 (+1.15%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Innate Pharma NASDAQ:IPHA$2.20 +0.01 (+0.64%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Terns Pharmaceuticals NASDAQ:TERN$7.52 +0.02 (+0.21%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
